2008
DOI: 10.1021/jm8007085
|View full text |Cite
|
Sign up to set email alerts
|

Design, Synthesis, and Biological Evaluation of a Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain

Abstract: We report herein the synthesis of a series of 19 2-hydroxyisoquinoline-1,3(2H,4H)-dione derivatives variously substituted at position 7 aimed at inhibiting selectively two-metal ion catalytic active sites. The compounds were tested against HIV-1 reverse transcriptase (RT) polymerase, HIV-1 RT ribonuclease H (RNase H), and HIV-1 integrase (IN). Most compounds displayed poor inhibition of RT polymerase even at 50 microM. The majority of the synthesized compounds inhibited RNase H and IN at micromolar concentrati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
96
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 111 publications
(98 citation statements)
references
References 49 publications
1
96
1
Order By: Relevance
“…Some of these inhibitors were initially discovered as HIV-1 integrase inhibitors (85,89) and were designed as active-site-directed compounds that would bind divalent metals at the integrase or RNase H active site (2,8,9,21,42,87,88). Acylhydrazone-based (11,30,35,80), hydroxyisoquinolinedione-based (8,9), and naphthyridinonebased (84,95) compounds are three classes of HIV-1 RNHIs. Like most RNHIs, these compounds are based on metal-chelating pharmacophore scaffolds that have been optimized for potent inhibition of HIV-1 RNase H. Our data are consistent with previous results suggesting that naphthyridinone NAPHRHI binds to the RNase H active site of HIV-1 RT and extend these findings for XMRV RNase H (95).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Some of these inhibitors were initially discovered as HIV-1 integrase inhibitors (85,89) and were designed as active-site-directed compounds that would bind divalent metals at the integrase or RNase H active site (2,8,9,21,42,87,88). Acylhydrazone-based (11,30,35,80), hydroxyisoquinolinedione-based (8,9), and naphthyridinonebased (84,95) compounds are three classes of HIV-1 RNHIs. Like most RNHIs, these compounds are based on metal-chelating pharmacophore scaffolds that have been optimized for potent inhibition of HIV-1 RNase H. Our data are consistent with previous results suggesting that naphthyridinone NAPHRHI binds to the RNase H active site of HIV-1 RT and extend these findings for XMRV RNase H (95).…”
Section: Discussionmentioning
confidence: 99%
“…Such drugs would likely be active against all current drug-resistant viral strains, because the RNase H active site is located at the opposite end of the enzyme from the polymerase domain (ϳ50 Å away) that is currently targeted by nucleoside and nonnucleoside RT inhibitors (79). Several compounds have been found in recent years to effectively inhibit the RNase H activity of HIV-1 RT, including ␣,␥-diketo acids and derivatives (27,77,78,91), pyrimidinol carboxylic acids (43,47), hydroxytropolones (including ␤-thujaplicinol) (6,12,15,21,34), dimeric lactones (19), 1,3,4,5-tetragalloylapiitol (86), phenolic glycosides (10), vinylogous ureas (16,94), N-hydroxyimides (33,44), 2-hydroxyisoquinoline-1,3(2H,4H)-diones (8,9), acylhydrazones (11,30,35,80), and naphthyridinones (84,95). Although these inhibitors have been studied for the ability to inhibit HIV-1 RT, little is known about their effectiveness against other retroviral RTs, such as the gammaretroviral Moloney murine leukemia virus (MoMLV) and xenotropic murine leukemia virus-related virus (XMRV) RTs.…”
mentioning
confidence: 99%
“…For the biological properties of the title compound, see: Parkes et al (2003); Hang et al (2004); Billamboz et al (2008). For a related structure, see: Miao et al (1995).…”
Section: Related Literaturementioning
confidence: 99%
“…The title compound is known to inhibit metalloenzymes such as influenza endonuclease (Parkes et al, 2003), HIV-1 reverse transcriptase RNase H (Hang et al, 2004), and HIV-1 integrase (Billamboz et al, 2008). Here we report the crystal structure of the title compound, which was obtained from the deprotection of 2-benzyloxyisoquinoline-1,3(2H,4H)-dione by the use of boron tribromide.…”
Section: S1 Commentmentioning
confidence: 99%
See 1 more Smart Citation